ENVERIC BIOSCIENCES INC
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Enveric Biosciences stock, anticipating its price will rise significantly.
Financial Health
Enveric Biosciences is showing solid financial performance with good cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ENVB
Mind & Spirit
Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical outcomes matter
Progress hinges on trial results and regulatory decisions, which can move the share price sharply; outcomes are uncertain and binary.
High volatility potential
As a microcap, shares can rise or fall quickly on news or capital events; consider liquidity and position size carefully.
Research and regulation
Ongoing R&D and changing regulatory landscapes drive prospects; check filings and trial registries to follow developments.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
